The Future of Respiratory Syncytial Virus Disease Prevention and Treatment

Joseph B Domachowske, Evan J Anderson, Mitchell Goldstein, Joseph B Domachowske, Evan J Anderson, Mitchell Goldstein

Abstract

Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, young children, and older or immunocompromised adults. Although aerosolized ribavirin was licensed for RSV treatment on the basis of data demonstrating a reduced need for supplemental oxygen, ribavirin use is limited because of issues with efficacy, safety, and cost. Currently, the treatment of RSV is primarily supportive. New antiviral treatments for RSV are in the early stages of development, but it will be years until any of these may be licensed by the US Food and Drug Administration (FDA). Palivizumab, an RSV monoclonal antibody [immunoprophylaxis (IP)], has demonstrated effectiveness in disease prevention and is the only licensed IP for RSV disease in specific high-risk pediatric populations. Although its efficacy is well established, some challenges that may interfere with its clinical use include cost, need for monthly injections, and changing policy for use by the American Academy of Pediatrics (AAP). Preventing RSV disease would be possible through RSV vaccine development (e.g., live-attenuated, vector-based subunit, or particle-based). Alternatively, new long-acting monoclonal antibodies have demonstrated promising results in early clinical trials. Despite scientific advances, until new agents become available, palivizumab should continue to be used to reduce RSV disease burden in high-risk patients for whom it is indicated.

Keywords: American Academy of Pediatrics; High-risk preterm infants; Immunoprophylaxis; Monoclonal antibody; National Perinatal Association; Palivizumab; Respiratory syncytial virus; Treatment; Vaccine.

Figures

Fig. 1
Fig. 1
Targets of antiviral agents in phase 2/3 clinical development [, –29]. F fusion protein; G attachment glycoprotein; L large viral polymerase; M matrix protein; M2-1 protein, transcription factor; N nucleoprotein; P phosphoprotein
Fig. 2
Fig. 2
RSV antivirals, vaccines, and mAbs under phase 2/3 clinical development [37, 41]. E elderly; IP immunoprophylaxis; M maternal; mAb monoclonal antibody; P pediatric; RSV respiratory syncytial virus

References

    1. American Academy of Pediatrics . Respiratory syncytial virus. In: Kimberlin DW, Brady MT, Jackson MA, editors. Red Book: 2018–2021 Report of the Committee on Infectious Diseases. Grove Village: American Academy of Pediatrics; 2018. pp. 682–692.
    1. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–845.
    1. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J. 2002;21(7):629–632.
    1. Trang TP, Whalen M, Hilts-Horeczko A, Doernberg SB, Liu C. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: a single-center retrospective cohort study and review of the literature. Transpl Infect Dis. 2018 doi: 10.1111/tid.12844.
    1. Simões EAF, Bont L, Manzoni P, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018;7(1):87–120.
    1. Chemaly RF, Aitken SL, Wolfe CR, Jain R, Boeckh MJ. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis. 2016;18(4):634–636.
    1. Xing Y, Proesmans M. New therapies for acute RSV infections: where are we? Eur J Pediatr. 2019;178(2):131–138.
    1. Ralston SL, Lieberthal AS, Meissner HC. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2015;134(5):e1474–e1502.
    1. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543–546.
    1. SYNAGIS [package insert]. Gaithersburg, MD: MedImmune, LLC. 2017.
    1. Geskey JM, Thomas NJ, Brummel GL. Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV) Biologics. 2007;1(1):33–43.
    1. Anderson EJ, Carosone-Link P, Yogev R, Yi J, Simões EAF. Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis. Pediatr Infect Dis J. 2017;36(8):699–704.
    1. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–1799.
    1. Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13(9):2138–2149.
    1. Piedimonte G. RSV infections: state of the art. Cleve Clin J Med. 2015;82(11 Suppl 1):S13–S18.
    1. DeVincenzo JP, Wilkinson T, Vaishnaw A, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010;182(10):1305–1314.
    1. DeVincenzo J, Tait D, Oluwayi O, et al. Safety and efficacy of oral RV521 in a human respiratory syncytial virus (RSV) phase 2a challenge study. Am J Respir Crit Care Med. 2018;197:A7715.
    1. Evaluation of ALX-0171 in Japanese children hospitalized for respiratory syncytial virus lower respiratory tract infection [NCT03418571]. 2019. . Accessed 2 Aug 2019.
    1. Terry M. Sanofi cuts a whopping 38 R&D programs to refocus on cancer, immunology, and rare diseases. Biospace website. 2019. . Accessed 23 May 2019.
    1. Safety, pharmacokinetics and antiviral activity of RV521 against RSV [NCT03258502]. . 2017. . Accessed 12 Aug 2019.
    1. Coakley E, Ahmad A, Larson K, et al. LB6. EDP-938, a novel RSV N-Inhibitor, administered once or twice daily was safe and demonstrated robust antiviral and clinical efficacy in a healthy volunteer challenge study. Open Forum Infect Dis. 2019;6(suppl 2):S995.
    1. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019 doi: 10.1136/bmj.l5021.
    1. Novavax announces topline results from phase 3 PrepareTM trial of ResVax™ for prevention of RSV disease in infants via maternal immunization [press release]. Gaithersburg, MD: Novavax, Inc. 2019. . Accessed 23 May 2019.
    1. Study of safety, reactogenicity and immunogenicity of GlaxoSmithKline’s (GSK) respiratory syncytial virus (RSV) maternal unadjuvanted vaccine in healthy pregnant women (aged 18 to 40 years) and their infants [NCT04126213]. . 2020. . Accessed 28 Aug 2020.
    1. A phase 2B placebo-controlled, randomized study of a respiratory syncytial virus (RSV) vaccine in pregnant women [NCT04032093]. . 2019. . Accessed 12 Sep 2019.
    1. Aliprantis A, Wolford D, Caro L, et al. A randomized, double-blind, placebo-controlled trial to assess the safety and tolerability of a respiratory syncytial virus (RSV) neutralizing monoclonal antibody (MK-1654) in healthy subjects. Poster presented at IDWeek 2018; October 6, 2018; San Francisco, CA. Poster 1971.
    1. Blanco JCG, Boukhvalova MS, Morrison TG, Vogel SN. A multifaceted approach to RSV vaccination. Hum Vaccin Immunother. 2018;14(7):1734–1745.
    1. Fearns R, Deval J. New antiviral approaches for respiratory syncytial virus and other mononegaviruses: inhibiting the RNA polymerase. Antiviral Res. 2016;134:63–76.
    1. Nicholson EG, Munoz FM. A review of therapeutics in clinical development for respiratory syncytial virus and influenza in children. Clin Ther. 2018;40(8):1268–1281.
    1. Toovey S, Peng C, Yuan H, et al. Ziresovir (AK0529): update on clinical development for the treatment of respiratory syncytial virus (RSV) disease (O30). Oral presentation presented at 11th International Respiratory Syncytial Virus Symposium; November 2, 2018; Asheville, NC.
    1. Anti-RSV study in Chinese patients (ASCENT) [NCT03699202]. . 2019. . Accessed 7 July 2020.
    1. Study to evaluate safety and antiviral activity of doses of JNJ-53718678 in children (>=28 days to <=3 years) with respiratory syncytial virus infection [NCT03656510]. . 2019. . Accessed 03 Aug 2019.
    1. Martinon-Torres F, Rusch S, Huntjens D, et al. Antiviral effects, pharmacokinetics (PK) and safety of the respiratory syncytial virus (RSV) fusion protein inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected infants with bronchiolitis, in the phase 1b study 53718678RSV1005. Poster presented at IDWeek 2018; October 3–7, 2018; San Francisco, CA. Poster 1958.
    1. Stevens M, Rusch S, DeVincenzo J, et al. Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study. J Infect Dis. 2018;218(5):748–756.
    1. Cass L, Davis A, Murray A, et al. Safety and pharmacokinetic profile of PC786, a novel inhibitor of respiratory syncytial virus L-protein polymerase, in a single and multiple-ascending dose study in healthy volunteer and mild asthmatics. Poster presented at IDWeek 2018; October 3–7, 2018; San Francisco, CA. Poster 1335.
    1. A study to assess EDP-938 for the treatment of acute upper respiratory tract infection with respiratory syncytial virus in adult subjects (RSVP) [NCT04196101]. . 2020. . Accessed 28 Aug 2020.
    1. RSV vaccine and mAb snapshot. Vaccine Resource Library and PATH website. 2020. . Accessed 7 July 2020.
    1. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89(4):405–421.
    1. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–434.
    1. Wright M, Piedimonte G. Respiratory syncytial virus prevention and therapy: past, present, and future. Pediatr Pulmonol. 2011;46(4):324–347.
    1. GlobalData. Respiratory syncytial virus (RSV): forecast in Asia-Pacific markets to 2028. . 2019. Accessed 23 June 2020.
    1. Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18(10):e295–e311.
    1. Rossey I, Saelens X. Vaccines against human respiratory syncytial virus in clinical trials, where are we now? Expert Rev Vaccines. 2019 doi: 10.1080/14760584.2019.1675520.
    1. Safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or placebo, delivered as nose drops to RSV-seronegative children 6 to 24 months of age [NCT03916185]. . 2019. . Accessed 21 Oct 2019.
    1. Evaluating the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-seronegative infants 6 to 24 months of age [NCT03227029]. . 2019. . Accessed 11 Oct 2019.
    1. Evaluating the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-seronegative infants and children 6 to 24 months of age [NCT03422237]. . 2019. . Accessed 11 Oct 2019.
    1. Evaluating the safety and immune response to a single dose of a respiratory syncytial virus (RSV) vaccine in infants and children [NCT01893554]. . 2019. . Accessed 11 Oct 2019.
    1. A study to assess safety, tolerability and immunogenicity of the live attenuated hRSV vaccine rBCG-N-hRSV (EVA-VRS01) [NCT03213405]. . 2019. . Accessed 11 Oct 2019.
    1. Rey-Jurado E, Soto J, Galvez N, Kalergis AM. A safe and efficient BCG vectored vaccine to prevent the disease caused by the human respiratory syncytial virus. Hum Vaccin Immunother. 2017;13(9):2092–2097.
    1. RSV investigational vaccine in RSV-seropositive infants aged 12 to 23 months [NCT02927873]. . 2019. . Accessed 2 Aug 2019.
    1. Respiratory syncytial virus (RSV) investigational vaccine in infants aged 6 and 7 months likely to be unexposed to RSV [NCT03636906]. . 2019. . Accessed 12 Sep 2019.
    1. A study to evaluate the safety, reactogenicity, and immunogenicity of adenovirus serotype 26 based respiratory syncytial virus pre-fusion (Ad26.RSV.Pre-F) vaccine in RSV-seronegative toddlers 12 to 24 months of age [NCT03606512]. . 2019. . Accessed 2 Aug 2019.
    1. A study of an Ad26.RSV.preF-based regimen in the prevention of reverse transcriptase polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in adults aged 65 years and older [NCT03982199]. . 2019. . Accessed 2 Aug 2019.
    1. Bavarian Nordic announces positive data from phase 2 extension study of its universal RSV vaccine [press release]. Copenhagen, Denmark: Bavarian Nordic A/S. 2018. . Accessed 2 Aug 2019.
    1. RSV-MVA-BN vaccine phase II trial in ≥ 55 year old adults [NCT02873286]. . 2019. . Accessed 12 Aug 2019.
    1. Clinical trials. Novavax website. 2019. . Accessed 14 Aug 2019.
    1. Anderson EJ, DeVincenzo JP, Simões EAF, et al. SENTINEL1: Two-season study of respiratory syncytial virus hospitalizations among US infants born at 29 to 35 weeks’ gestational age not receiving immunoprophylaxis. Am J Perinatol. 2020;37(4):421–429.
    1. Hacimustafaoglu M, Celebi S, Aynaci E, et al. The progression of maternal RSV antibodies in the offspring. Arch Dis Child. 2004;89(1):52–53.
    1. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36(5):248–255.
    1. Yeung CY, Hobbs JR. Serum-gamma-G-globulin levels in normal premature, post-mature, and "small-for-dates" newborn babies. Lancet. 1968;1(7553):1167–1170.
    1. Chu HY, Englund JA. Maternal immunization. Clin Infect Dis. 2014;59(4):560–568.
    1. A study to describe the safety and immunogenicity of a RSV vaccine in healthy adults [NCT03529773]. . 2019. . Accessed 23 May 2019.
    1. Madhi SA, Polack FP, Piedra PA, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020;383(5):426–439.
    1. A study of a RSV vaccine when given together with Tdap in healthy nonpregnant women aged between 18 to 49 years [NCT04071158]. . 2019. . Accessed 12 Sep 2019.
    1. Pfizer Inc. The free library website. 2019. . Accessed 25 Sep 2019.
    1. A study of a vaccine against respiratory syncytial virus (RSV) when given alone and together with a vaccine against diphtheria, pertussis and tetanus (Tdap) viruses to healthy non-pregnant women [NCT04138056]. . 2020. . Accessed 28 Aug 2020.
    1. Gagneur A, Pinquier D, Quach C. Immunization of preterm infants. Hum Vaccin Immunother. 2015;11(11):2556–2563.
    1. Heikkinen T, Valkonen H, Waris M, Ruuskanen O. Transmission of respiratory syncytial virus infection within families. Open Forum Infect Dis. 2015 doi: 10.1093/ofid/ofu118.
    1. Boyce TG, Mellen BG, Mitchel EF, Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137(6):865–870.
    1. Langston C, Kida K, Reed M, Thurlbeck WM. Human lung growth in late gestation and in the neonate. Am Rev Respir Dis. 1984;129(4):607–613.
    1. Griffin MP, Khan AA, Esser MT, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017 doi: 10.1128/AAC.01714-16.
    1. Nirsevimab. NIH website. 2019. . Accessed 23 Sep 2019.
    1. A study to evaluate the safety of MEDI8897 for the prevention of medically attended respiratory syncytial virus (RSV) lower respiratory track infection (LRTI) in high-risk children [NCT03959488]. . 2019. . Accessed 2 Aug 2019.
    1. US FDA grants breakthrough therapy designation for potential next-generation RSV medicine MEDI8897 [press release]. AstraZeneca PLC 2019. . Accessed 23 May 2019.
    1. A study to evaluate the safety and efficacy of MEDI8897 for the prevention of medically attended RSV LRTI in healthy late preterm and term infants (MELODY) [NCT03979313]. . 2019. . Accessed 12 Sep 2019.
    1. A study to evaluate the safety and efficacy of MEDI8897 for the prevention of medically attended RSV LRTI in healthy preterm infants. (MEDI8897 Ph2b) [NCT02878330]. . 2019. . Accessed 12 Sep 2019.
    1. Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–425.
    1. Safety, tolerability, and pharmacokinetics of MK-1654 in infants (MK-1654-002) [NCT03524118]. . 2019. . Accessed 2 Aug 2019.
    1. Maas B, Aliprantis A, Wolford D, et al. RSV monoclonal antibody (MK-1654) phase 1 pharmacokinetics (PK) in healthy adults and population PK modeling to support pediatric development. Poster presented at IDWeek 2018; October 3–7, 2018; San Francisco, CA. Poster 1384.
    1. Carbonell-Estrany X, Simões EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125(1):e35–e51.
    1. Walker EP. MedPage Today website. FDA advisers turn down new RSV drug. . 2010. Accessed 19 Sep 2019.
    1. Motavizumab. . 2019. . Accessed 12 Sep 2019.
    1. Regeneron to discontinue development of suptavumab for respiratory syncytial virus [press release]. Tarrytown, NY: Regeneron Pharmaceutical, Inc. 2017. . Accessed 23 May 2019.
    1. Iwane MK, Farnon EC, Gerber SI. Importance of global surveillance for respiratory syncytial virus. J Infect Dis. 2013;208(Suppl 3):S165–S166.
    1. Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52(4):556–569.
    1. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958.
    1. Aranda SS, Polack FP. Prevention of pediatric respiratory syncytial virus lower respiratory tract illness: perspectives for the next decade. Front Immunol. 2019;10:1006.
    1. Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants [supplementary appendix] N Engl J Med. 2020;383(5):415–425.
    1. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415–420.
    1. Goldstein M, Phillips R, DeVincenzo JP, et al. National Perinatal Association 2018 respiratory syncytial virus (RSV) prevention clinical practice guideline: an evidence-based interdisciplinary collaboration. Neonatol Today. 2017;12(10):1–14.
    1. Goldstein M, Krilov LR, Fergie J, et al. Respiratory syncytial virus hospitalizations among US preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics guidance on immunoprophylaxis: 2012–2016. Am J Perinatol. 2018;35(14):1433–1442.
    1. Rajah B, Sánchez PJ, Garcia-Maurino C, Leber A, Ramilo O, Mejias A. Impact of the updated guidance for palivizumab prophylaxis against respiratory syncytial virus infection: a single center experience. J Pediatr. 2017;181:183–188.e1.
    1. Krilov LR, Fergie J, Goldstein M, Brannman L. Impact of the 2014 American Academy of Pediatrics immunoprophylaxis policy on the rate, severity, and cost of respiratory syncytial virus hospitalizations among preterm infants. Am J Perinatol. 2019;37(2):174–183.
    1. Kong AM, Krilov LR, Fergie J, et al. The 2014–2015 national impact of the 2014 American Academy of Pediatrics guidance for respiratory syncytial virus immunoprophylaxis on preterm infants born in the United States. Am J Perinatol. 2018;35(2):192–200.
    1. American Academy of Pediatrics Committee on Infectious Diseases: American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415–20. Reaffirmed February 2019.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit